


# Index



## A

- Abciximab, 68, 70
- Absorption, 5
- Acetaminophen, 171–174, 179, 198
  - hepatotoxicity, 173, 174
  - pharmacokinetics, 172–173, 174
- Acetylcholine, 8
- Acetylsalicylic acid, 64, 69
- Acute leukemia, 116
- Acyclovir, 30–31
- Adjusted body weight, 3, 4
  - creatinine clearance, 11
- Adjuvant analgesics, 176
- Age-based dosing, 141
- Alcohol consumption, 198, 199
- Alemtuzumab, 131
- Alfentanil, 178, 179
- Alkylating agents, 117–119, 130
- Alprazolam, 88
- Alteplase (rt-PA), 63, 69
- Amikacin, 19
- Aminoglycoside, 5, 19–20
  - concentration-dependent, 15, 16
  - dosing, 2–3, 33
  - pediatric patient and, 145, 146, 148, 149
  - weight to use for, 36
- Aminopenicillins, 17
- Aminophylline, 90, 91
- Amiodarone, 83, 84, 85
- Amitriptyline, 179, 192
- Amoxicillin, 17, 184, 187
- Amphotericin, 16
- Amphotericin B, 29–30
- Ampicillin, 17, 198
- Ampicillin/sulbactam, 17
- Analgesics, 171–181, 195–196, 199
  - pediatric, 141–142, 149
- Anidulafungin, 29
- Anthracyclines, 124–125, 127, 130
- Antiarrhythmics, 83–85, 94
- Antibiotics, 16–26, 36–37, 184, 186–187, 199
- Antibody reduction therapy, 163
- Antibody-mediated rejection, 164
- Anticoagulant, dosing, 69–70
- Anticoagulants, 45–46
  - dosing, 69–70
  - pediatric, 143–144, 149
- Anticonvulsants, 9
- Antidepressants, 192
- Antiepileptic agents, 97–107
- Antifungal agents, 16, 26–30, 37
- Antihypertensive agents, 79–82
- Antimetabolite agents, 122–123, 130
- Antimicrobial agents
  - dosing, 15–16
  - dosing, sample calculations, 33–35
  - pediatric, 145–146, 149
  - summary table, 36–38
- Antimicrotubule agents, 121–122, 130
- Antineoplastic agents, 117–127, 193
  - dosing, 109–137
  - pediatric, 146–147, 149
- Antiplatelet dosing, 64–70
- Antiproliferative agents, 158–160, 165
- Antipsychotic agents, 9
- Antituberculosis agents, 25–26, 37
- Antiviral agents, 16, 30–33, 38, 187–188, 200
- Apixaban, 62, 69
- Area under the curve, 110
- Argatroban, 59, 69
- Arsenic trioxide, 126, 131
- Aspirin, 64, 65, 69, 143
- Atenolol, 79
- Atorvastatin, 10, 193–194, 195, 199
- Atracurium, 86
- Azathioprine, 160
- Azithromycin, 16, 186, 187, 199

Azoles, 26–28, 37

Aztreonam, 18

**B**

Bariatric surgery, 183–202

medications and, 198

Basiliximab, 156, 162, 165

Belatacept, 162, 165

Benefield, Emily C., 139–151

Benzodiazepines, 8, 87–88, 90

Beta-blockers, 9, 79–81, 94

Beta-lactams, 15, 16–18, 36, 146

Bivalirudin, 59, 69

anticoagulation in PCI, 59

HIT treatment, 59

Bleomycin, 126, 131

Body mass index (BMI), 2, 3

pediatric, 139–140

Body size descriptors, 3

Body surface area (BSA), 2, 141

alternatives, 112–113

determination, 110–112

Breast cancer, 113–114, 117

Brentuximab vedotin, 126, 127, 131

Bronchodilators, 90

Bupropion, 192

Buspirone, 192

Busulfan, 112, 117–118, 130, 147, 148, 149

**C**

Calcineurin inhibitors, 156–158, 161, 165

Calcium channel blockers, 81–82, 94

Calcium products, 196, 198

Capping doses, 113

Carbamazepine, 97, 99, 102–103, 106

dosing weight, 102–103

Carbapenems, 16, 18, 36

Carboplatin, 119–121, 127, 130

sample calculation, 128–129

Cardiovascular agents, 193–195, 199

Cardiovascular/resuscitation, 143, 149

Carfilzomib, 125, 127, 130

Carmustine, 118, 130

Caspofungin, 28

Cefazolin, 17, 146

Cefdinir, 18

Cefepime, 33

Cefotaxime, 18

Cefoxitin, 17

Ceftaroline, 18

Ceftazidime, 18

Ceftriaxone, 18

Cefuroxime, 18

Celecoxib, 175, 179

Centers for Disease Control and Prevention, 139–140

Cephalosporins, 16, 17–18, 149

Chemotherapy dosing, 113–114, 117

Chloral hydrate, 142

Chronic leukemia, 116

Cidofovir, 32

Cilostazol, 67, 70

Ciprofloxacin, 21

Cisatracurium, 85, 86

Cisplatin, 121, 127, 130

Citalopram, 192

CKD-EPI equation, 7, 8

Clarithromycin, 22

Clearance, 6–8

Clevidipine, 81–82

Clindamycin, 16, 24, 25

Clobazam, 105

Clofarabine, 130

Clonazepam, 192

Clopidogrel, 65, 66, 67, 70

Clozapine, 192

Cockcroft-Gault equation, 7, 8, 34–35, 120, 127

Colistin, 23–24

Colorectal cancer, 114, 117

Concentration-dependent activity, 15, 16

Cook, Aaron M., 15–43

Corticosteroids, 91–92, 95, 162

Costimulatory blockade, 162

Creatinine clearance, 6–7

estimation, 10–11

equations, 8

Critical care, 77–96

Critically ill drugs, 93–94

Cyclophosphamide, 118, 130

Cyclosporine, 5, 156–157, 158, 198

Cyclosporine-corticosteroid studies, 161

Cytarabine, 122, 130, 147

Cytomegalovirus, 31–32, 38

**D**

Dabigatran, 61, 62, 69

Dalbavancin, 20

Dalteparin, 69

VTE therapeutic dosing, 53

Daptomycin, 16, 20–21, 36

Darunavir, 187, 200

Daunorubicin, 124, 130

Depolarizing agents, 85–86, 87

Dexmedetomidine, 89, 90

Diabetic foot infection case, 34–35

Diazepam, 5, 88, 192

Didanosine, 188

Digoxin, 83–84, 194, 195, 198, 199

Dihydropyridines, 81–82

Diltiazem, 81

Distribution, 5–6

Docetaxel, 121, 130

Dofetilide, 84

Doripenem, 18

Dose capping, 163

Doxorubicin, 124, 130, 146–147, 149

Doxycycline, 23

Drug dosing, weight based, 2

Duloxetine, 190, 192, 199

**E**

Echinocandins, 16, 28–29, 37

Edoxaban, 62, 69

Efavirenz, 188

Elder, Stacy, 45–74

Emtricitabine, 187, 188, 200

Endocrine agents, 193–195, 199

End-organ function, 110

Enoxaparin, 5, 49–50, 51, 52, 57, 69

Matisse dosing trials, 57

pediatric, 143, 144, 149

VTE therapeutic studies, 53–55, 56

Epirubicin, 124, 130

Eptifibatidate, 67, 68, 70

Ertapenem, 18

Erythromycin, 22, 186, 187, 199

Eslicarbazepine acetate, 105

Esmolol, 80

Ethambutol, 25, 198

Ethosuximide, 105, 198

Etoposide, 123, 130, 147

Everolimus, 161, 162, 165

Excretion, 6–7

Extravasation, 78

Ezogabine, 105

**F**

Felbamate, 105

Fentanyl, 177–178, 179

pediatric, 141–142

Fibrinolytics, 62–64, 69  
 Filgrastim, 131  
 Fixed-dose chemotherapy, 113  
 Flannery, Alexander H., 15–43  
 Fluconazole, 26, 27, 28  
 Flucytosine, 30  
 Fludarabine, 122, 130  
 Fluoroquinolones, 16, 21, 36  
 Fluorouracil, 122, 130  
 Fluoxetine, 192  
 Fondaparinux, 57–59, 69  
   Matisse dosing trials, 57  
   VTE prophylaxis, 57–58  
 Foscarnet, 31, 32  
 Fosfomycin, 25  
 Fosphenytoin, 98, 100  
 Free-fat mass, 3, 4  
 Furosemide, 194, 195, 199

## G

Gabapentin, 105  
 Ganciclovir, 31–32  
 Gastrointestinal therapy, 196, 199  
 Gemcitabine, 123, 130  
 Genetic animal model, 6  
 Gengraf, 157  
 Gentamicin, 7, 19, 36, 145  
 Glomerular filtration rate, 6–7  
 Glucocorticoids, 9  
 Glycopeptides, 20, 36  
 GP IIb/IIIa inhibitors, 67–68, 70  
 Granulocyte-colony stimulating factors, 126–127  
 Gynecological cancer, 114, 117

## H

Haloperidol, 191, 192, 200  
 Healthy living, 9  
 Hematologic cancers, 115–117  
 Heparin, 69  
 Herpes simplex virus, 31, 38  
 Histamine-2 receptor antagonists, 92, 95  
 Hydralazine, 82  
 Hydrochlorothiazide, 198  
 Hydroxychloroquine, 188, 190, 199  
 Hydroxyzine, 142

## I

Ibuprofen, 174, 175, 179  
 Ibutilide, 84  
 Idarubicin, 125, 130

Ideal body weight (IBW), 2, 3, 4  
   creatinine clearance, 10  
   pediatric, 140  
 Ifosfamide, 118–119, 130  
 Imatinib, 125, 130, 193, 200  
 Imipenem, 18  
 Immunomodulators, 188–190, 199  
 Immunosuppressants, 188–190, 199  
 Immunosuppression, 153–170  
   medication dosing, 165  
 Induction agents, 165  
 Influenza, 32–33, 38  
 Inotropes, 78–79  
 Insulin glargine, 9, 10  
 Insulin resistance, 8–9  
 Intensive care unit  
   complications risk, 78  
   informatics challenges, 78  
   pharmacokinetic considerations, 77–78

Intravenous direct thrombin inhibitors, 59–60  
 Intravenous immunoglobulin, 162–164, 165  
   weight-based dosing, 163  
 Irinotecan, 123, 130  
 Iron products, 196–197, 198  
 Isoniazid, 198  
 Itraconazole, 27  
 Ixabepilone, 121, 130

## K

Ketorolac, 174–175, 179

## L

Labetalol, 79  
 Lacosamide, 97, 104, 106  
   dosing weight, 104  
 Lamivudine, 187, 188, 200  
 Lamotrigine, 105, 191, 192  
 Lean body weight (LBW), 2, 3, 4  
   creatinine clearance, 10  
 Length-based tape, 143  
 Levetiracetam, 97, 103, 104, 106  
   dosing weight, 103–104  
 Levofloxacin, 21  
   renal dose adjustment, 10  
 Levothyroxine, 194, 195, 198, 199  
 Lidocaine, 84, 85  
 Lifestyle changes, 9  
 Linezolid, 16, 22, 186, 199  
 Liraglutide, 9  
 Lithium, 191, 192, 200

L-norgestrel, 198  
 Loading doses, 5  
 Lorazepam, 88, 192  
 Lorcaserin, 9  
 Low molecular weight heparin, 46, 47, 49, 69  
   ACS therapeutic dosing, 56–57  
   bariatric surgery, 50–51, 52  
   dosing studies, 49–51, 53  
   medical patients, 49, 51  
   nonbariatric surgery/trauma patients, 49–50, 51  
   therapeutic dosing, 52–56  
   VTE prophylaxis dosing, 47, 49  
   VTE therapeutic dosing, 52  
 Lung cancer, 115, 117  
 Lymphoma, 116–117

## M

Macrolides, 22–23, 36  
 Mammalian target of rapamycin inhibitors, 161–162  
 Mardis, B. Andrew, 153–170  
 Mardis, Caitlin R., 153–170  
 Martin, Craig A., 15–43  
 Matisse medication dosing trials, 57  
 Matzke nomogram for vancomycin, 35  
 Mechlorethamine, 119, 130  
 Medication dosing, 4–5  
 Melphalan, 112, 119, 130  
 Meperidine, 142  
 Mercaptopurine, 146, 149  
 Meropenem, 18  
 Metabolic syndrome, 9  
 Metabolism, 6  
 Metformin, 194–195, 199  
 Methotrexate, 123, 127, 130, 189, 190, 199  
   pediatric, 147  
 Methylphenidate, 192  
 Methylprednisolone, 91  
 Methylxanthine derivatives, 90–91, 95  
 Metoprolol, 80  
 Metronidazole, 16  
 Metropolitan Life Insurance Company of New York Data, 2  
 Micafungin, 28  
 Midazolam, 5, 87–88, 191, 199  
 Minocycline, 23  
 Modification of Diet in Renal Disease (MDRD), 7  
 Monobactams, 16, 18, 36

Monoclonal antibodies, 125–126, 127, 131, 155–156  
 Morphine, 142, 177, 178, 179, 195–196, 199  
 Moxifloxacin, 21, 186, 199  
 Multivitamins, 197  
 Mycophenolate mofetil, 158–160, 162  
 Mycophenolate sodium, 158–160  
 Mycophenolic acid, 165, 189, 190, 199

## N

Naltrexone/bupropion, 9  
 National Health and Nutrition Examination Survey (NHANES), 140  
 National Health Center for Statistics, 140  
 Nebivolol, 80  
 Nelfinavir, 187, 188, 200  
 Nemecek, Branden D., 183–202  
 Neoral, 156–157  
 Neostigmine, 87  
 Nesbit, Suzanne Amato, 171–181  
 Neurologic medications, 190–192, 199, 200  
 Neuromuscular blocker reversal agents, 94  
 Neuromuscular blockers, 85–87, 94  
 Neuromuscular reversal agents, 87  
 Nicardipine, 81, 82  
 Nifedipine, 81  
 Nitrofurantoin, 187  
 Nitroglycerin, 82  
 Nondepolarizing agents, 85, 87  
 Nondihydropyridines, 81  
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 174–175, 179  
 Norethisterone, 198  
 Nortriptyline, 176, 179  
 Nosocomial pneumonia case, 33–34  
 Nutrition supplementation, 196–198, 199  
 Nutritional animal model, 6

## O

Obesity  
   pediatric, 139  
   prevalence of, 1  
 Olanzapine, 192  
 Omeprazole, 196, 199  
 Oncology, 199, 200  
 Opioids, 149, 177–179  
 Oral anticoagulants, 60–62, 69

Oral contraceptives, 9  
 Oritavancin, 20  
 Orlistat, 9  
 Oseltamivir, 32–33  
 Osteomyelitis, 34  
 Ouellette, Jacquelyn F., 139–151  
 Overdose, pediatric, 142  
 Overweight, pediatrics, 139  
 Oxazolidinones, 22–23, 36  
 Oxcarbazepine, 105, 192

## P

Paclitaxel, 112, 121–122, 130  
 Paralytics, pediatric, 141–142, 149  
 Paroxetine, 192  
 Patient-specific factors, 8–9  
 Pediatrics, 139–151  
 Pegfilgrastim, 131  
 Penicillin G, 17  
 Penicillins, 16–17, 198  
 Pentostatin, 130  
 Peramivir, 33  
 Perampanel, 105  
 Percent body fat, 2  
 Performance status, 110  
 Pharmacodynamic changes, 8–9  
 Pharmacokinetic/pharmacodynamic (PK/PD) targets, 15–16  
 Pharmacokinetics  
   absorption, 5  
   acetaminophen, 172–173, 174  
   distribution, 5–6  
   excretion/clearance, 6–8  
   ICU patients, 77–78  
   metabolism, 6  
   obese pediatric patients, 140–141  
   sampling, 10  
 Phenobarbital, 97, 99, 101–102, 106, 191, 192, 200  
   dosing weight, 101–102  
 Phentermine, 9  
 Phentermine/topiramate, 9  
 Phenytoin, 97–89, 100, 106, 191–192, 198, 200  
   equations, 98  
   loading dose, 98–99, 100  
   loading dose calculation, 105–106  
   maintenance dosing, 99, 100  
 Phosphodiesterase III inhibitor, 67, 70  
 Pilch, Nicole A., 153–170  
 Piperacillin, 17

Piperacillin/tazobactam, 34  
 Platinum analogues, 119–121, 130  
 Plerixafor, 127, 131  
 Polyclonal antibodies, 155–156  
 Polyenes, 29–30, 37  
 Polymyxins, 23–24, 37  
 Posaconazole, 27, 28  
 Prasugrel, 65–66, 70  
 Predicted normal weight, 3, 4  
 Prednisolone, 91  
 Prednisone, 189, 190, 199  
 Pregabalin, 105  
 Primidone, 105  
 Procainamide, 83, 84  
 Procarbazine, 119, 130  
 Propofol, 88–89, 142, 149  
 Propranolol, 5, 79–80  
 Propylthiouracil, 198  
 Protease-activated receptor 1 inhibitors, 66–67, 70  
 Psychiatric medications, 190–192, 199, 200  
 P2Y12 inhibitors, 64–66, 70  
 Pyrazinamide, 25

## Q

Quetelet, Adolphe, 2  
 Quetelet index, 2  
 Quetiapine, 192

## R

Rabbit anti-thymocyte globulin, 155–156, 165  
 Raltegravir, 188  
 Ranitidine, 92  
 Rasburicase, 127, 131  
 Remifentanyl, 178, 179  
 Resuscitation, 143  
 Reteplase, 63, 69  
 Rifampin, 25, 198  
 Risperidone, 192  
 Ritonavir, 188, 200  
 Rituximab, 126, 131  
 Rivaroxaban, 61–62, 69  
 Rocuronium, 85–86  
 Roux-en-Y gastric bypass, 184–185  
   medication levels post, 200  
   pharmacokinetics, 185–198  
   pharmacokinetics, post, 199–200  
 Rufinamide, 105

**S**

Salazar-Corcoran equation, 7, 8, 35  
 Sandimmune, 156–157  
 Sedation, 148  
 Sedatives, 87–90, 94  
   pediatric, 141–143, 149  
 Selective serotonin reuptake inhibitors, 192  
 Serotonin and norepinephrine reuptake inhibitors, 192  
 Sertraline, 192, 199  
 Severely obese, children, 139  
 Shank, Brandon R., 1–13, 109–137  
 Sirolimus, 161, 162, 165, 189–190, 199  
 Sodium nitroprusside, 82  
 Solid tumors, 113–115  
 Sotalol, 80  
 Stavudine, 188  
 Stem cell transplantation, 115–116, 117  
 Streptomycin, 25  
 Subcutaneous Xa inhibitor, 57–59  
 Succinylcholine, 85, 87, 142, 149  
 Sufentanil, 178, 179  
 Sulfamethoxazole/trimethoprim, 25  
 Sulfonylureas, 9  
 Sunitinib, 125, 130

**T**

Tacrolimus, 157–158, 160, 165, 190, 198, 199  
 Tamoxifen, 193, 200  
 Targeted therapies, 125, 130  
 Taxanes, 127  
 Tedizolid, 22  
 Teicoplanin, 20  
 Temozolomide, 193, 199  
 Tenecteplase, 63, 69  
 Teniposide, 147  
 Tenofovir, 188, 200  
 Tetracyclines, 16, 22–23, 37  
 Thalidomide, 125, 130  
 Theophylline, 90, 91  
 Thiamine, 197, 198  
 Thiazolidinedione, 9  
 Thiopental, 89, 90  
 Thiotepa, 119, 130  
 Thymoglobulin, 155–156  
 Ticagrelor, 66, 70  
 Ticarcillin, 17  
 Ticlopidine, 64, 70  
 Tigecycline, 23

Time-dependent activity, 15, 16

Tinzaparin, 69  
   VTE therapeutic dosing studies, 55  
 Tirofiban, 68, 70  
 Tobramycin, 19, 33, 145  
 Topiramate, 105  
 Topoisomerase inhibitors, 123–124, 130  
 Topotecan, 124, 130  
 Total body weight (TBW), 2, 4  
   creatinine clearance, 11  
 Transplantation immunosuppression, 153–155  
 Trazodone, 192  
 Treatment intent, 110  
 Triazoles, 16  
 Tricyclic antidepressants, 9, 176–177  
 24-hour creatinine clearance, 7, 8

**U**

Underdose, pediatric, 142–143  
 Unfractionated heparin, 46–47, 69  
   bariatric surgery dosing, 46–47  
   dosing studies, 48  
   Matisse dosing trials, 57  
   pediatric, 143, 144, 149  
   therapeutic dosing, 47  
   VTE prophylaxis dosing, 46

**V**

Valganciclovir, 31, 32  
 Valproic acid, 97, 99, 100–101, 106  
   dosing weight, 100  
 Vancomycin, 16, 20–21, 22, 34, 35  
   pediatric, 145–146, 148, 149  
 Vasodilators, 82, 94  
 Vasopressors, 78–79  
 Vecuronium, 85, 86, 87  
 Venlafaxine, 176, 179, 192  
 Verapamil, 81  
 Vigabatrin, 105  
 Vinca alkaloids, 127  
 Vincristine, 113, 122, 130, 127  
 Viral infections, post-transplant, 164  
 Vitamin B<sub>12</sub>, 197, 198  
 Vitamin D, 197, 198, 199  
 Vitamin supplementation, 196–198, 199  
 Vorapaxar, 66–67, 70  
 Voriconazole, 26–27, 28

**W**

Waldfogel, Julie, 171–181  
 Warfarin, 60–61, 62, 69  
   pediatric, 143, 144, 149  
 Weight  
   assessment, 110  
   measures of, 2–4  
 Weight-based dosing, 141  
 Weight-loss medications, 9–10  
 World Health Organization, 2, 139–140

**Z**

Zidovudine, 188, 200  
 Zimmerman, David E., 77–96, 97–107  
 Ziprasidone, 192  
 Zolpidem, 192  
 Zonisamide, 105

# Notes

---

# Notes

---

# Notes

---